Oct 28 (Reuters) - EyePoint Pharmaceuticals Inc
:
* EYEPOINT PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM 16-WEEK DATA FOR ONGOING PHASE 2 VERONA CLINICAL TRIAL OF DURAVYU™ FOR DIABETIC MACULAR EDEMA
* EYEPOINT PHARMACEUTICALS INC - FULL TOPLINE DATA EXPECTED IN Q1 2025
* EYEPOINT PHARMACEUTICALS INC: FAVORABLE SAFETY PROFILE CONTINUES WITH NO DURAVYU-RELATED OCULAR OR SYSTEMIC SAES TO DATE
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.